Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

First International Summit on Interventional Pharmacoeconomics

Opportunities to Optimize Cancer Policies Panel Discussion

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Varsha Gandhi, PhD, on Ibrutinib

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Apr

Today In Oncology

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Related Videos

Opportunities to Optimize Cancer Policies Panel Discussion

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Varsha Gandhi, PhD, on Ibrutinib

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

How Cannabis Use May Be Accelerating Breast and Testicular Cancer Rates in AYAs

Japanese Study Looks at Rates of Cancer Therapy–Related AML

Researchers Identify Blood-Based Biomarker for Cancer Risk in People With Lynch Syndrome

Final Report on Pralsetinib in Advanced RET Fusion–Positive NSCLC

New ASH HematOmics Program Offers Blood Cancer Data Integration Tool to Accelerate Research